Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

@article{Covington2008PharmacokineticPA,
  title={Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.},
  author={Paul Covington and R Tomaras Christopher and Michael D Davenport and Penny R. Fleck and Qais A Mekki and Elisabeth R. Wann and Aziz Karim},
  journal={Clinical therapeutics},
  year={2008},
  volume={30 3},
  pages={499-512}
}
BACKGROUND Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes (T2D). OBJECTIVES This study was conducted to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles and explore the efficacy of multiple oral doses of alogliptin in patients with T2D. METHODS In this randomized, double-blind, placebo-controlled, parallel-group study, patients with T2D between the ages of 18 and 75… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

The Korean journal of internal medicine • 2015
View 15 Excerpts
Highly Influenced

Alogliptin: a new addition to the class of DPP-4 inhibitors

Diabetes, metabolic syndrome and obesity : targets and therapy • 2009
View 5 Excerpts
Highly Influenced

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Diabetes, metabolic syndrome and obesity : targets and therapy • 2014
View 6 Excerpts
Highly Influenced

Alogliptin benzoate for management of type 2 diabetes

Vascular health and risk management • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Pharmacokinetic and pharmacodynamic profiles of SYR - 322 , a novel inhibitor of dipeptidyl peptidase - IV , in rats , dogs , and monkeys

RJ Christopher, JM Davenport, S Gwaltney
Diabetes • 2007

The role of gut hormones in glucose homeostasis.

The Journal of clinical investigation • 2007

Similar Papers

Loading similar papers…